Globalization and cognitive enhancement: Emerging social and ethical challenges for ADHD clinicians

Current Psychiatry Reports

Volumn 15, Issue 9, 2013, Pages

  Singh, Ilina ^a   Filipe, Angela M ^a   Bard, Imre ^b   Bergey, Meredith ^c   Baker, Lauren ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^c BRANDEIS UNIVERSITY   (United States)

Author keywords

Adderall; Addiction; ADHD; Attention deficit hyperactivity disorder; Clinical practice; Cognitive enhancement; Culture; Diagnosis; Diagnostic criteria; Diversion; Ecology; Ethics; Global mental health; Globalization; Hyperactivity; International; Medicalization; Prevalence; Psychiatry; Ritalin; Stimulants; Treatment

Indexed keywords

AMPHETAMINE PLUS DEXAMPHETAMINE; METHYLPHENIDATE; PSYCHOSTIMULANT AGENT; CENTRAL STIMULANT AGENT;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL PRACTICE; COGNITIVE ENHANCEMENT; COGNITIVE THERAPY; GLOBALIZATION; HEALTH CARE ACCESS; HUMAN; MEDICAL DECISION MAKING; MEDICAL ETHICS; PRESCRIPTION; SOCIAL ASPECT; STIGMA; VALIDATION STUDY; BIOETHICS; ETHICS; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; INTERNATIONAL COOPERATION; REVIEW; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIOETHICAL ISSUES; CENTRAL NERVOUS SYSTEM STIMULANTS; ETHICS, MEDICAL; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; INTERNATIONALITY;

EID: 84881114172     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-013-0385-0     Document Type: Article

References (119)

1. Conrad P. Identifying hyperactive children: The medicalization of deviant behaviour. Lexington, MA: Lexington Books; 1976.
2. Conrad P. The medicalization of society: On the transformation of human conditions into treatable disorders. Baltimore, Johns Hopkins UP;2007.
3. Shrag P, Divoky D. The myth of the hyperactive child and other means of child control. New York: Pantheon;1975.
4. Barkley R. Issues in the diagnosis of attention-deficit/hyperactivity disorder in children. Brain Dev. 2003;25:77-83. (Pubitemid 36170303)
5. Malacrida C. Medicalization, Ambivalence and Social Control: Mothers' Descriptions of Educators and ADD/ADHD. Health (London). 2004;8(1):61-80. (Pubitemid 38184098)
6. Horwitz A. Creating mental illness. Chicago: Chicago UP; 2002.
7. Sonuga-Barke EJ, Schlotz W, Kreppner J. Differentiating developmental trajectories for conduct, emotion and peer problems following early deprivation. Monographs of the Society for Research in Child Development. 2010;75:102-24.
8. Parens E, Johnson J. Facts, values and Attention Deficit Hyperactivity Disorder (ADHD): an update on the controversies. Child Adolesc Psychiatry Ment Health. 2009;3:1. doi: 10.1186/1753-2000-3-1.
9. Mayes R, Bagwell C, Erkulwater J. ADHD and the Rise in Stimulant Use Among Children. Harv Rev Psychiatry. 2008;16:151-66. (Pubitemid 351883195)
10. Singh I. Beyond Polemics: Science and ethics of ADHD. Nat Rev Neurosci. 2008;9(12):957-64.
11. • Parens E. On good and bad forms of medicalization. Bioethics. 2013;27(1):28-35. An important development in the medicalization debates that moves the concept on from older versions into interesting and useful new territory.
12. Singh I. Human development, nature and nurture: Working beyond the divide. BioSocieties. 2012. doi: 10.1057/biosoc.2012.20.
13. Worthman CM, Protsky PM, Schechter DS, Cummings CA. Formative experiences: The interaction of caregiving, culture and developmental biology. Cambridge, UK: CUP; 2010.
14. Layard R, Dunn J. A Good Childhood. London: Penguin; 2009.
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM) - 5. Virginia, USA: American Psychiatric Publishing; 2013.
16. Centres for Disease Control and Prevention (CDC). Mental health surveillance among children- United States, 2005-2011. Atlanta, GA: US Dept of Health and Human Services; 2013.
17. Schwarz A, Cohen S. A.D.H.D. Seen in 11% of U.S. Children as Diagnoses Rise. The New York Times March. 2013(31).
18. Scheffler RM, Hinshaw SP, Modrek S, Levine P. The global market for ADHD medications. Health Aff. 2007;26:450-7.
19. Cornejo JW, Osio O, Sanchez Y, et al. Prevalence of attention deficit hyperactivity disorder in Columbian children and teenagers. Rev Neurol. 2005;40(12):716-22 [in Spanish]. (Pubitemid 47279274)
20. Pineda D, Ardila A, Rosselli M, et al. Prevalence of attention - deficit/hyperactivity disorder symptoms in 4-17 year old children in the general population. J Abnorm Child Psychol. 1999;27(6):455-62. (Pubitemid 30010750)
21. Pino P, Mojarro-Praxedes M. Hyperkinetic D disorders: double-phase epidemiological study of a population from Sevilla. An Psiquiatria. 2001;17(6):265-70 [in Spanish].
22. Catalá-López F, Peiró S, Ridao M, Sanfélix-Gimeno G, Gènova-Maleras R, Catalá MA. Prevalence of attention deficit hyperactivity disorder among children and adolescents in Spain: a systematic review and meta-analysis of epidemiological studies. BMC Psychiatry. 2012; doi: 10.1186/1471-244X-12-168
23. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942-8. (Pubitemid 46972911)
24. Polanczyk G, Jensen P. Epidemiological considerations in Attention Deficit Hyperactivity Disorder: A review and update. Child Adolesc Psychiatric Clin N Am. 2008;17:245-60. (Pubitemid 351265397)
25. Gomez R, Harvey J, Quick C, et al. DSM-IV AD/HD: confirmatory factor models, prevalence, and gender and age differences based on parent and teacher ratings of Australian primary school children. J Child Psychol Psychiatry. 1999;40(2):265-74. (Pubitemid 29078371)
26. Levy F, Hay DC, McStephen M, et al. Attention deficit hyperactivity disorder: a category or a continuum? Genetic analysis of a large-scale twin study. J Am Child Adolesc Psychiatry. 1997;36(6):737-44. (Pubitemid 27250436)
27. Hinshaw SP, Scheffler RM, Fulton BD, Aase H, Banaschewski T, Cheng W, Mattos P, Holte A, Levy F, Sadeh A, Sergeant JA, Taylor E, Weiss MD. International Variation in Treatment Procedures for ADHD: Social Context and Recent Trends. Psychiatr Serv. 2011:62(5). http://ps.psychiatryonline.org/ article.aspx?articleID=116182
28. INCB. Psychotropic Substances: Statistics for 2011. International Narcotics Control Board Report. 2012. http://www.incb.org/documents/ Psychotropics/technical-publications/2012/en/Eng-2012-PUBlication.pdf. Accessed 30 May 2013.
29. • Zuvekas S, Vitiello B. Stimulant medication use among US children: A twelve-year perspective. Am J Psychiatry. 2012;169(2):160-66. A careful longitudinal study showing a slowing in overall rates of stimulant medication use among US children over the twelve year period, but a worrying increase in use among adolescents.
30. INCB. International Narcotics Control Board. Report of the International Narcotics Control Board for 2007. 2007. http://www.incb.org/pdf/annual-report/ 2007/en/annual-report-2007.pdf
31. Timimi S, Taylor E. ADHD is best understood as a cultural construct. Br J Psychiatry. 2004;184:8-9. (Pubitemid 38085208)
32. Moffitt TE, Melchior M. Why does the worldwide prevalence of childhood attention deficit hyperactivity disorder matter? Am J Psychiatry. 2007;164(6):856-8. (Pubitemid 46972898)
33. Amaral OB. Psychiatric disorders as social constructs: ADHD as a case in point. Am J Psychiatry. 2007;164:1612-3. (Pubitemid 350069745)
34. Bass JK, Bolton PA, Murray LK. Do not forget culture when studying mental health. The Lancet. 2007;370(9591):918-9. (Pubitemid 47384836)
35. Watters E. Crazy like us: The globalization of the American psyche. New York: Free Press; 2010.
36. Kirmayer L. Beyond the 'new cross-cultural psychiatry': Cultural biology, discursive psychology and the ironies of globalization. Transcult Psychiatry. 2006;43(1):126.
37. Moynihan R, Doran E, Henry D. Disease mongering is now part of the global health debate. PloS Medicine. 2008;5(5):e106. (Pubitemid 351760891)
38. Dumit J. Drugs for Life: How Pharmaceutical Companies Define Our Health. Durham and London: Duke University Press; 2012.
39. Grand Challenges in Global Mental Health Initiative. www. grandchallengesgmh.nimh.nih.gov
40. •• The Lancet. Global Mental Heath. 2011. http://www.thelancet. com/series/global-mental-health-2011 The series is the second of two Lancet special issues that outlines key challenges in global mental health. The series helped mobilize the NIH, WHO and UN to regard mental health in the context of global public health trajectories and goals.
41. The Lancet. Global Mental Heath. 2007. http://www.thelancet.com/series/ global-mental-health
42. Summerfield D. Afterword: Against "global mental health". Transcut Psychiatry. 2012;49(3):1-12. doi: 10.1177/1363461512454701.
43. Bemme D, D'Souza N. Global Mental Health and its Discontents. somatosphere.net. 2012. http://somatosphere.net/2012/07/global-mental-health- and-its-discontents.html
44. Farmer P. An Anthropology of Structural Violence. Curr Anthropol. 2004;45(3).
45. Canino G, Alegria M. Psychiatric diagnosis- is it universal or relative to culture? J Child Psychol Psychiatry. 2008;49(3):237-50. (Pubitemid 351348264)
46. Wakefield JC, Pottick KJ, Kirk SA. Should the DSM-IV criteria for conduct disorder consider social context? Am J Psychiatry. 2002;159:380-6. (Pubitemid 34184731)
47. Rohde LA, Szobot C, Polanczyk G, Schmitz M, Martins S, Tramontina S. Attention-Deficit/Hyperactivity Disorder in a Diverse Culture: Do Research and Clinical Findings Support the Notion of a Cultural Construct for the Disorder? Biol Psychiatry. 2005;57:1436-41. (Pubitemid 40798565)
48. Bronfenbrenner U. The ecology of human development. Camridge, MA: Harvard UP; 1979.
49. Merrill RM, Lyon JL, Baker RK, Gren LH. Attention deficit hyperactivity disorder and increased risk of injury. Advanced Medical Science. 2009;54:20-6.
50. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602. (Pubitemid 40973434)
51. World Health Organization. Constitution. 1946/2006. http://www.who.int/ governance/eb/who-constitution-en.pdf
52. Fulton BD, Scheffler RM, Hinshaw SP, Levine P, Stone S, Brown TT, Modrek S. National Variation of ADHD Diagnostic Prevalence and Medication Use: Health Care Providers and Education Policies. Psychiatr Serv. 2009;60(80).
53. Getahun G, Jacobsen SJ, Fassett MJ, Chen W, Demissie K, Rhoads GG. Recent Trends in Childhood Attention-Deficit/Hyperactivity Disorder. JAMA Pediatr. 2013;167(3):282-8.
54. Froehlich TE, Lamphear BP, Epstein JN, Barbesi WJ, Katusic SK, Kahn RS. Prevalence, recognition, and treatment of Attention-Deficit/Hyperactivity Disorder in a national sample of US children. Arch Pediatr Adolesc Med. 2007;161(9):857-64. (Pubitemid 47360887)
55. Zima BT, Bussing R, Tang L, Zhang L, Ettner S, Belin TR, et al. Quality of care for childhood attention-deficit/hyperactivity disorder in a managed care Medicaid program. J Am Acad Child Adolesc Psychiatry. 2010;49(12):1225-37.
56. Zito JM, Safer DJ, Devadatta S, Gardner JF, Thomas D, Coombes P, et al. Pediatrics. 2008;121(1):e157-163.
57. Morgan PL, Staff J, Hillemeier MM, Farkas G, Maczuga S. Racial and Ethnic Disparities in ADHD Diagnosis From Kindergarten to Eighth Grade. Pediatr. 2013; doi: 10.1542/peds.2012-2390
58. Frazier TW, Shattuck PT, Narendorf SC, Cooper BP, Wagner M, Spiznagel EL. Prevalence and correcolates of psychotropic medication use in adolescents with an autism spectrum disorder with and without caregiver-reported attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011;21:571-9.
59. DosReis S, Barksdale CL, Sherman A, Maloney K, Charach A. Stigmatizing experiences of parents of children with a new diagnosis of ADHD. Psychiatr Serv. 2010;61(8):811-6. doi: 10.1176/appi.ps.61.8.811.
60. Hinshaw SP, Stier A. Stigma as Related to Mental Disorders. Annu Rev Clin Psychol. 2008;4:367-93. doi: 10.1146/annurev.clinpsy.4.022007.141245. (Pubitemid 351668623)
61. • Mueller AK, Fuermaier ABM, Koerts J, and Tucha L. Stigma in attention deficit hyperactivity disorder. Atten Defic Hyperact Disord. 2012;4(3):101-114. doi: 10.1007/s12402-012-0085-3 DOI: 10.1007%2Fs12402-012- 0085-3. A key, comprehensive meta-analysis of the stigma literature in ADHD.
62. Singh I. Doing their jobs: Mothering with Ritalin in a culture of mother-blame. Soc Sci Med. 2004;59(6):1193-205. (Pubitemid 38759879)
63. Koro-Ljungberg M, Bussing R. The management of courtesy stigma in the lives of families with teenagers with ADHD. J Fam Issues. 2009;30:1175-200.
64. Frazzetto G, Keenan S, Singh I. Bambini e le droghe: The case of ADHD and Ritalin in Italy. BioSocieties. 2008;2(4):393-412.
65. O'Driscoll C, Heary C, Hennessy E, McKeague L. Explicit and implicit stigma towards peers with mental health problems in childhood and adolescence. J Child Psychol Psychiatry. 2012;53(10):1054-62. doi: 10.1111/j.1469-7610.2012. 02580.x.
66. Singh I. A disorder of anger and aggression: Children's perspectives on Attention Deficit/Hyperactivity Disorder in the UK. Soc Sci Med. 2011;73:889-96.
67. Bröer C, Heerings M. Neurobiology in public and private discourse: the case of adults with ADHD. Sociol Health & Ill. 2013;35(1):49-65.
68. Filipe AM. Through the looking-glass: a critical review of sociology and medicine towards the diagnosis of ADHD. Configurações. 2011;8:73-86.
69. Edwards C, Howlett E. Putting knowledge to trial: 'ADHD parents' and the evaluation of alternative therapeutic regimes. Soc Sci Med. 2013;81:34-41.
70. Edwards C, Howlett E, Akrich M, Rabeharisoa V. Attention deficit hyperactivity disorder in France and Ireland: parents' groups' scientific and political framing of an unsettled condition. 2012. http://www.csi.mines- paristech.fr/working-papers/DLWP.php?wp=WP-CSI-024.pdf. Accessed 30 May 2013.
71. Ortega F. The Cerebral Subject and the Challenge of Neurodiversity. BioSocieties. 2009;4:425-45.
72. Behague D. Psychiatry and Politics in Pelotas, Brazil: The Equivocal Quality of Conduct Disorder and Related Diagnoses. Med Anthropol Q. 2009;23(4):455-82.
73. Wilcox CE, Washburn R, Patel V. Seeking help for attention deficit hyperactivity disorder in developing countries: a study of parental explanatory models in Goa. India Soc Sci Med. 2007;64(8):1600-10. (Pubitemid 46436243)
74. Bruckner TA, Hodgson A, Mahoney CB, Fulton BD, Levine P, Scheffler RM. Health care supply and county-level variation in attention-deficit hyperactivity disorder prescription medications. Pharmacoepidemiol Drug Saf. 2012;21(4):442-9. doi: 10.1002/pds.2264.
75. Wang PS, Berglund P, Olfson M, Pincus HA. Wells, Kessler RC. Failure and Delay in Initial Treatment Contact After First Onset of Mental Disorders in the National Comorbidity Survey Replication Arch Gen Psychiatry. 2005;62(6):603-13.
76. Schwarz A. Attention Disorder or Not, Pills to Help in School. The New York Times. 9 October 2012. http://www.nytimes.com/2012/10/09/health/attention- disorder-or-not-children-prescribed-pills-to-help-in-school.html?src=me&ref= general
77. Singh I. Not Robots: Children's perspectives on authenticity, moral agency and stimulant drug treatments. J Med Ethics. 2012. doi: 10.1136/medethics-2011-100224.
78. Singh I. VOICES Study: Final Report video clip 'Doctors': http://youtu.be/lFyglFDR650
79. Froehlich T. Strive to diagnose better, not to prescribe less. NY Times; 2012. http://www.nytimes.com/roomfordebate/2012/06/09/fewer-prescriptions-for- adhd-less-drug-abuse/adhd-should-be-diagnosed-better
80. Green JG, Gruber MJ, Kessler RC, Lin JY, McLaughlin MA, Sampson NA, et al. Diagnostic validity across racial and ethnic groups in the assssment of adolescent DSM-IV disorders. Int J Methods Psychiatr Res. 2012;21(14):311-20.
81. • Nigg J. Future directions in ADHD etiology research. J Clin Child Adolesc Psychol. 2012;41(4):524-33. Key overview of the importance of specifying environmental and historical contributions to ADHD etiology.
82. Frank A. The Wounded Storyteller: Body, Illness, and Ethics. Chicago: University of Chicago Press; 2010.
83. Kleinman A. Rethinking Psychiatry: from cultural category to personal experience. New York: The Free Press; 1988.
84. Good B. Medicine, Rationality, and Experience: An Anthropological Perspective. Cambridge: Cambridge UP; 1994.
85. Singh I, Kelleher KJ. Brain enhancement in children. In: Farah M, Chatterjee A, editors. Neuroethics in Practice. Oxford, UK: Oxford University Press; 2013.
86. Advokat C. What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD). Neuroscience & Biobehav Rev. 2010;34(8):1256-66.
87. Hall WD, Lucke JC. The enhancement use of neuropharmaceuticals: more scepticism and caution needed. Addiction. 2010;105(12):2041-3.
88. Repantis D, Schlattmann P, Laisney O, Heuser I. Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res. 2010;62:187-206.
89. •• Smith MF, Farah MJ. Are prescription stimulants "smart pills"? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychol Bull. 2011;137(5):717-41. The most authoritative overview to date of the scientific literature on cognitive enhancement, and a meta-analysis of US prevalence estimates.
90. Rabiner DL, Anastopoulos AD, Costello EJ, Hoyle RH, McCabe SE, Swartzwelder HS. Motives and perceived consequences of nonmedical ADHD medication use by college students are students treating themselves for attention problems? J Atten Disord. 2009;13(3):259-70.
91. • Ilieva I, Boland J, Farah MJ. Objective and subjective cognitive enhancing effects of mixed amphetamine salts in healthy people. Neuropharmacology. 2012;64(1):496-505. The first systematic investigation of the important question of how perceptions of cognitive enhancement correlate with objectively measurable outcomes.
92. Vrecko S. Just how cognitive is "cognitive enhancement"? On the significance of emotions in university students' experiences with study drugs. AJOB Neuroscience. 2013;4(1):4-12.
93. •• Ragan CI, Bard I, Singh I. What should we do about student use of cognitive enhancers? An analysis of current evidence. Neuropharmacology. 2013;64:588-95. doi: 10.1016/j.neuropharm.2012.06.016. Authoritative overview of cross-national prevalence estimates in cognitive enhancement; and an assessment of need for policy intervention.
94. Franke AG, Bonertz C, Christmann M, Huss M, Fellgiebel A, Hildt A, et al. Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry. 2010;43:1-7.
95. Humle T, Friislund M. 'Study drugs' vinder frem på universiteter. In: Information Online. 2010. http://www.information.dk/236139.
96. Hansard. HC Deb 4 June 2013, cc1072W-1073W.
97. Italian National Committee for Bioethics (CNB), Presidency of the Council of Ministers. Neuroscience and Pharmacological Cognitive Enhancement: Bioethical Aspects. 2013. http://www.palazzochigi.it/bioetica/eng/opinions/ Neuroscience-and-pharmacological-cognitive-enhancement-20130613.pdf
98. Swanson JM, Wigal T, Volkow ND. Contrast of medical and non-medical use of stimulant drugs: Basis for the distinction, and risk of addicition: Comment on Smith and Farah. Psychol Bull. 2011;137(5):742-8.
99. Rimsza ME, Moses KS. Substance abuse on the college campus. Pediatr Clin North Am. 2005;52(1):307-19. (Pubitemid 40340945)
100. Friedman RA. The Changing Face of Teenage Drug Abuse - The Trend toward Prescription Drugs. N Engl J Med. 2006;354(14):1448-50.
101. Schwarz A. Attention-Deficit Drugs Face New Campus Rules. The New York Times. 30 April 2013.
102. Kaye S, Darke S. The diversion and misuse of pharmaceutical stimulants: what do we know and why should we care? Addiction. 2012;107(3):467-77.
103. Rabiner DL. Stimulant Prescription Cautions: Addressing Misuse. Diversion and Malingering Curr Psychiatry Rep. 2013;15(7):1-8.
104. Talbot M. Can a daily pill really boost your brain power? The Guardian Online. 2009. http://www.guardian.co.uk/science/2009/sep/20/neuroenhancers-us- brain-power-drugs
105. Poulin C. Medical and nonmedical stimulant use among adolescents: from sanctioned to unsanctioned use. Can Med Assoc J. 2001;1658:1039-44. (Pubitemid 32964866)
106. Garnier-Dykstra LM, Caldeira KM, Vincent KB, O'Grady KE, Arria AM. Nonmedical use of prescription stimulants during college: Four-year trends in exposure opportunity, use, motives, and sources. J Am Coll Health. 2012;60(3):226-34.
107. McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use, and diversion of abusable prescription drugs. J Am Coll Health. 2006;54(5):269-78. (Pubitemid 43439968)
108. Peterkin AL, Crone CC, Sheridan MJ, Wise TN. Cognitive performance enhancement: Misuse of self-treatment. J Atten Disord. 2010; doi: 10.1177/1087054710365980
109. Bostrom N, Sandberg A. Cognitive enhancement: methods, ethics, regulatory challenges. Sci Eng Ethics. 2009;15(3):311-41.
110. Harris J. Enhancing Evolution: The Ethical Case for Making Better People. Princeton University Press; 2007
111. Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, Campbell P, et al. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature. 2008;456(7223):702-5.
112. Larriviere D, Williams MA, Rizzo M, Bonnie RJ. Responding to requests from adult patients for neuroenhancements Guidance of the Ethics. Law and Humanities Committee Neurology. 2009;73(17):1406-12.
113. British Medical Association (BMA). Boosting your Brainpower: Ethical Aspects of Cognitive Enhancement. Report, Nov 2007.
114. CEST. Psychiatric Drugs and Expanded Uses: an Ethical Perspective. 2009. http://www.ethique.gouv.qc.ca/index.php?option=com-docman&Itemid= 22&lang=en
115. Singh I, Kelleher KJ. Neuroenhancement in young people: proposal for research, policy and clinical management. Am J Bioeth Neurosci. 2010;1(1):3-16.
116. •• Graf WD, Nagel SK, Epstein LG, Miller G, Nass R, Larriviere D. Pediatric neuroenhancement Ethical, legal, social, and neurodevelopmental implications. Neurology. 2013;80(13):1251-60. First public statement by a professional group (American Academy of Neurology) on pediatric cognitive enhancement.
117. Sonuga-Barke EJ, Koerting J, Smith E, McCann DS, Thompson M. Early detection and intervention for attention deficit hyperactivity disorder. Expert Review of Neurotherapeutics. 2011;11(4):557-63.
118. Singh I, Sinnott-Armstrong W, Savulescu J. (in press). Bioprediction, Biomarkers, and Bad Behavior: Scientific, Legal, and Ethical Challenges. Oxford UP.
119. Singh I, Rose N. Biomarkers in psychiatry: Promises and perils in the real world. Nature. 2009;460(7252):202-7.